NY-CLINIQUE
2.2.2024 15:01:27 CET | Business Wire | Press release
Clinique and Icahn School of Medicine at Mount Sinai today announced a philanthropic partnership to establish the Mount Sinai-Clinique Healthy Skin Dermatology Center. The Center will develop forward-thinking research in dermatology, exploring the biological underpinnings of how skin ages, skin allergies and inflammatory or eczematous skin conditions, including eczema (or atopic dermatitis) and contact dermatitis. Rooted in a shared mission to conduct dermatological research that improves patients’ lives, the partnership will focus on applicable scientific discovery and leading-edge innovation to modernize allergy science in order to identify innovative solutions for these skin conditions.
Research conducted under the Mount Sinai-Clinique Healthy Skin Dermatology Center aims to uncover scientific findings to accelerate the creation of new topical and systemic treatments that help alleviate allergic skin conditions. The priority is to bridge basic science with practical application in the clinic to improve people’s lives through healthy skin. By investigating healthy skin, along with the skin of those with atopic dermatitis and other allergic skin disorders, the researchers may learn how to significantly slow the visible signs of aging in all people as well as in patients with eczema, who show signs of premature or accelerated aging. Insights from this research aim to spur advances in the field of dermatology and skin health. Additionally, they will inform and inspire Clinique in future product innovation to offer further solutions for people with allergic or sensitive skin.
“As a brand that has offered dermatologist guided solutions and allergy tested solutions since its inception, Clinique is proud to partner with the renowned institution of Icahn Mount Sinai and its team of physician-scientists, led by a world-renowned expert in allergic and inflammatory skin diseases, Dr. Emma Guttman. We are inspired by the team’s dedication to the research and future discoveries of allergic skin and its life impact, including aging. We are energized by our mutual commitment and steadfast belief that great skin can be created and maintained for all. I am confident that this first-of-its-kind partnership will enable groundbreaking research by leading physician-scientists dedicated to advancing allergy science,” Michelle Freyre, President, Global Brands, Clinique.
Dr. Emma Guttman, MD, PhD, Waldman Professor and System Chair, Department of Dermatology at the Icahn School of Medicine, a trailblazer in dermatologic science, has dedicated her career to bridging science with practice intended to improve patients’ lives. Her work has led to novel therapeutic targets for patients suffering from inflammatory skin conditions. Drawing inspiration from her personal and family history of eczema and other allergic conditions, Dr. Guttman has made it her mission to alleviate sensitive skin.
“Years of chronic inflamed skin plays a role in premature aging. Extensive research has helped us understand the molecular map of skin conditions associated with allergy such as eczema and contact dermatitis, and we’re now at a pivotal point in addressing these conditions and more. With Clinique’s support, we will continue to actively explore targeted approaches to reversing eczematous and allergic skin conditions with the goal of creating and sustaining healthy skin. In turn, we want to use this understanding to address and prevent the process of age-related inflammation or ‘inflammaging’ in the first place,” says Dr. Guttman, who also directs the Center of Excellence in Eczema at Mount Sinai and the Laboratory of Inflammatory Skin Diseases at Icahn Mount Sinai.
The laboratory of Inflammatory Skin Diseases at Icahn Mount Sinai has a major focus on atopic dermatitis, contact dermatitis, alopecia areata, and other inflammatory skin diseases. It has made paradigm-shifting discoveries on the immunologic basis of atopic dermatitis, opening the door to new therapeutics. Dr. Guttman’s lab developed the only comprehensive molecular maps of atopic dermatitis, defining skin differentiation and immune-circuits characterizing this disease across phenotypes and ages. This work on atopic dermatitis/eczema has contributed directly to many of the recently developed treatments for this disease, earning Dr. Guttman and her lab a unique place as being a top leader in dermatology and immunology worldwide.
Clinique has a long-standing history of partnering with dermatologists, including its Founding Dermatologist, Norman Orentreich, MD, and incorporating patients’ insights in its innovation since 1968. His children, Catherine Orentreich, MD, and David Orentreich, MD, the brand’s Guiding Dermatologists, continue their father’s legacy for Clinique. Dr. David Orentreich is Assistant Clinical Professor of Dermatology at Icahn Mount Sinai, and he and Dr. Catherine Orentreich are members of the Mount Sinai Dermatology Advisory Board.
In this meaningful mission, Clinique has made a philanthropic commitment of $5 million over seven years for the advancement and evolution of allergy science through the partnership and founding of the Mount Sinai-Clinique Healthy Skin Dermatology Center. The funds will be used to recruit the best and brightest physicians and scientists, and provide resources for the most advanced equipment, clinical and laboratory space, and key support staff. The studies conducted by the Mount Sinai-Clinique Healthy Skin Dermatology Center will include all ages, genders, races and ethnicities, and will also investigate the effects of factors such as diet, exercise, and stress on the skin of healthy people. Mount Sinai predicts that with Clinique’s support, critical breakthroughs will be fast-tracked, from the earliest stages of the multiyear partnership.
About Mount Sinai Health System:
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, more than 400 outpatient practices, more than 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it. Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,400 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2023-2024.
About Clinique:
In 1968, a beauty editor asked a leading New York City dermatologist, “Can great skin be created?” The answer: yes. And with that yes, Clinique was born. Today Clinique is the #1 Dermatologist Brand in Skincare in the US* and #1 Dermatologist Brand in Makeup in the US**, offering its dermatologist guided, allergy tested solutions for remarkable skin results. The brand is sold in 107 markets worldwide. Clinique’s clinical solutions are informed by years of research, working with dermatologists, scientists, and ophthalmologists. All Clinique formulas are designed to deliver powerful efficacy with rigorous safety —clinically proven, allergy tested, and 100% fragrance free.
*Source: Circana, U.S. Prestige Beauty Total Measured Market, Skincare Unit Sales, Derm Brand Attribute, 12 Months Ending December 2023
**Source: Circana, U.S. Prestige Beauty Total Measured Market, Makeup Unit Sales, Derm Brand Attribute, 12 Months Ending December 2023
Derm Brand is defined as a brand that was founded or developed by a dermatologist and/or is dermatologist recommended.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240202954316/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
